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Abstract
Background: Coverage is used as one indicator of needle and syringe program (NSP) effectiveness. At the individual
level, coverage is typically defined as an estimate of the proportion of a person who injects drugs’ (PWID) injecting
episodes that utilise a sterile syringe. In this paper, we explore levels of individual syringe coverage and its changes
over time.
Methods: Data were extracted from 1889 interviews involving 502 participants drawn from the Melbourne drug user
cohort study (MIX).
We asked questions relating to participants syringe acquisition, distribution and injecting frequency within the two weeks
before interview. We created a dichotomous coverage variable that classified participants as sufficiently (≥100 %) covered
if all their injecting episodes utilised at least one sterile syringe, and insufficiently (<100 %) covered if not. We categorised
participants as “consistently covered” if they were sufficiently covered across interviews; as “consistently uncovered” if they
were insufficiently covered across interviews; and “inconsistently covered” if they oscillated between coverage states.
Chi-square statistics tested proportions of insufficient coverage across sub-groups using broad demographic, drug use
and service utilisation domains. Logistic regression tested predictors of insufficient coverage and inconsistently covered
categorisation.
Results: Across the sample, levels of insufficient coverage were substantial (between 22–36 % at each interview wave).
The majority (50 %) were consistently covered across interviews, though many (45 %) were inconsistently covered.
We found strong statistical associations between insufficient coverage and current hepatitis C virus (HCV) infection (RNA
+). Current prescription of opioid substitution therapy (OST) and using NSPs as the main source of syringe acquisition
were protective against insufficient coverage.
Conclusion: Insufficient coverage across the sample was substantial and mainly driven by those who oscillated between
states of coverage, suggesting the presence of temporal factors. We recommend a general expansion of NSP services and
OST prescription to encourage increases in syringe coverage.
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Background
The coverage of a public health program can be defined
as the extent to which it reaches its intended population
[1]. It is an indicator of the effectiveness of public health
interventions in reducing public health risks.
Needle and syringe programs (NSPs) seek to avert
blood-borne virus (BBV) spread amongst people who in-
ject drugs (PWID) via the distribution of sterile needles
and syringes (hereafter referred to as syringe/s). The cover-
age achieved by NSPs at the population level refers to the
proportion of PWID reached by services. At the individual
level, coverage is typically defined as the proportion of a
PWID’s injecting episodes that utilise a sterile syringe [2].
The sharing of used syringes is a significant contributor
to the transmission of BBVs amongst PWID [3, 4]. It is es-
timated that globally, only 1–4 syringes are distributed per
PWID per month [5], well below the World Health
Organization (WHO) recommended rate of 200 syringes
per PWID per year [6].
Syringe coverage is mediated by context. Service man-
agement and funding [7], dispensation policy [8], inten-
sive policing practices [1, 9], cohesiveness of PWID
networks [2], spatial service access [10], and individual
demographics [11, 12] influence the ability of individuals
to attain sufficient syringes and service systems to pro-
vide sufficient coverage.
Previous research has shown that insufficient coverage
at the individual level is significantly associated with high-
frequency injecting and not using NSPs as a primary
source of syringe acquisition [2]. Insufficient individual-
level coverage has also been associated with syringe re-use
and receptive/distributive syringe sharing [11–13]. Despite
these findings, current understanding of the causes of in-
sufficient coverage is poor. Most research on individual
coverage has been cross-sectional and consequently un-
able to capture variation over time – hence Bluthenthal et
al.’s call for longitudinal investigation [11]. A greater un-
derstanding of coverage over time will also provide better
knowledge of the predictors of insufficient coverage and
enable better interventions.
The Australian context provides the ideal setting for
research on patterns of syringe coverage over time.
Australia’s early and comprehensive adoption of NSPs pre-
vented an HIV epidemic in PWID, in contrast to many
other countries [14, 15]. An estimated 3000+ syringe outlets
service an estimated population of 90,000 PWID [16],
distributing approximately 213 syringes per PWID per year
[12], in excess of WHO population-level recommendations
[6]. Despite greater opportunity to acquire syringes than
many of their international counterparts, an estimated 16–
37 % of Australian PWID experience insufficient coverage
[2, 12, 17]. Consequently, research exploring the individual
and structural determinants of insufficient coverage in
Australia provides important information for other settings.
In this paper we analyse six years of data from an
ongoing cohort of PWID in Melbourne, Australia. We
aim to:
 describe the characteristics of individuals with
recent insufficient coverage (insufficient syringe
acquisition to cover injecting episodes within the
past two weeks) across broad demographic, drug use
and service utilisation domains;
 explore how the proportion of individuals with
recent insufficient coverage changes over time;
 categorise participants according to their
longitudinal patterns of coverage; and
 identify exposure sub-groups independently associ-
ated with individual coverage and longitudinal
coverage pattern trajectories.
Methods
Melbourne injecting drug user cohort study
Data are drawn from the Melbourne injecting drug user
cohort study (MIX), which has been described in detail
elsewhere [18]. The cohort includes PWID recruited
through the original MIX recruitment phase in 2008–
2010 (n = 688), and those rolled into the study in 2011
via past involvement in the Networks II cohort (n = 69)
[19], resulting in 757 participants. Both MIX and Net-
works II sought to recruit regular injectors, and despite
some demographic differences between the MIX and
Networks II cohorts at the 2011 roll-in (mean age in
2011 was 29 in MIX, 35 in Networks II; 16 % in MIX
were born overseas, 31 % in Networks II; 54 % were cur-
rently on OST in MIX, 62 % in Networks II), the charac-
teristics of the cohorts at baseline (2005 for Networks II)
were comparable [19–21].
Eligibility criteria for the original MIX cohort were be-
ing aged 18–30 years and reporting injecting of heroin
and/or methamphetamine regularly (at least once a
month in the six months prior to recruitment).
Participant sample
As of February 2015 (dataset end), 2862 separate inter-
views had been collected over a maximum of seven an-
nual interview waves per participant. As the necessary
coverage questions were not introduced into the ques-
tionnaire until June 2010, all interviews prior to this date
(902 interviews, 184 participants) were excluded from
analysis. Furthermore, as we intended to analyse changes
to coverage longitudinally, only participants with two or
more interviews after June 2010 were retained, excluding
a further 71 participants. This process resulted in an
amended dataset of 502 participants and 1889 interviews
across a maximum of six separate interview waves. Study
retention was high, with 85 % of these participants hav-
ing at least three interviews.
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The demographic and drug use patterns of the total
cohort and the amended sample used in analysis were
similar, though current employment was 7 percentage
points higher, and current OST prescription 21 percent-
age points higher, among the amended sample. Compar-
isons between the two sets of data at first interview are
presented in Additional file 1.
Measures
To measure syringe retention, we asked the following
questions:
“In the last two weeks, how many new syringes in total
did you get?”
“In the last two weeks, how many syringes did you give
away or sell to others?”
The MIX questionnaire records past week use and
injecting frequency for 18 drug types. Past week inject-
ing frequencies for each drug type were summed to cre-
ate a total injecting frequency variable.
Using a method of calculating individual syringe cover-
age adapted from Bluthenthal et al. [11], we subtracted
the number of syringes sold or given away from the num-
ber of syringes acquired. We then multiplied past week
injecting frequency by two to create a consistent time
frame for the measure (rather than syringe collection be-
ing halved, as initial inspection showed less variance for
injection frequency, suggesting it is the more consistent
practice). We then divided the number of syringes
retained by past two-week injecting frequency and then
multiplied by 100, resulting in a percentage of injecting
episodes that utilised a sterile syringe. The formula for in-
dividual coverage measurement was therefore:
syringes acquired−syringes distributedð Þ
ðpast week injecting frequency x 2Þ  100
Recent individual coverage was considered to be suffi-
cient if every reported episode of injecting was covered
by at least one reported sterile syringe, or ≥100 % indi-
vidual coverage. A dichotomous variable, “recent cover-
age” (≥100 % coverage / <100 % coverage), was applied
to each interview with valid data, classifying participants
as either sufficiently or insufficiently covered for the two
weeks before interview.
Coverage was only calculated for participants who re-
ported both syringe acquisition and injecting within the
two-week period (as the absence of either parameter
precludes calculation). Missing data accounted for 44 %
(832 observations) of all coverage responses. Of these
missing data, most (602 observations, 72 % of all missing
responses) resulted from injecting abstinence.
Sub-group selection
We chose exposure variables a priori, including predictors
in Bluthenthal et al.’s [11] original coverage paper and re-
cent work by McCormack et al. [17]. Broadly, these sub-
groups fall within demographic, drug use characteristics
and service utilisation domains. Demographic: “sex”
(male/female), “Indigenous status” (yes/no), “WHO defin-
ition of youth” (≤24 years/>24 years); “highest level of edu-
cation” (<year 10/year 10–11/year 12, higher education,
trade), “weekly income” (around median: <$400/≥$400),
“employment status” (employed/unemployed), “stable ac-
commodation” (yes/no), “country of birth” (Australia/
other), “arrest (past twelve months)” (yes/no). Drug use
characteristics: “injecting career” (around median:
<13 years/≥13 years), “heroin injection (past month)” (yes/
no), “methamphetamine injection (past month)” (yes/no),
“Hazardous drinking scale score – derived from Audit-C
scale” (abstinent/<8 points/≥8 points) [22], “receptive syr-
inge sharing (past month) - derived from BBV-TRAQ-SV”
(yes/no), “injection of another person (past month) - de-
rived from BBV-TRAQ-SV” (yes/no), “been injected by an-
other person (past month) – derived from BBV-TRAQ-SV”
(yes/no), “BBV-TRAQ-SV injecting risk scale score” (con-
tinuous measure) [23], “hepatitis C virus serology (HCV)
status” (three categories: positive (RNA+)/exposed (Anti-
body+, RNA-)/negative (Antibody-, RNA-), “injecting
more than usual in the past six months” (yes/no), “solitary
injecting >80 % of the time” (yes/no). Service utilisation:
“current opioid substitution therapy prescription (OST)”
(yes/no), “NSP as usual source of syringe acquisition (past
month)” (yes/no). An amended version of the MIX ques-
tionnaire, relevant to this analysis, is presented in
Additional file 2: Appendix 1.
Analysis strategy
We categorised participants with at least two instances of
valid coverage data into three distinct subgroups according
to longitudinal experience of the dichotomised recent
coverage variable: “consistently covered” if all valid coverage
data was recorded as sufficient, “consistently uncovered” if
all valid coverage data was recorded as insufficient, and “in-
consistently covered” if participants had at least one change
between the two states of coverage across interviews.
The three coverage pattern groups were comparable in
terms of missing data and attrition patterns. In the consist-
ently covered group, 91 % of participants had three or more
interviews and 27 % missing coverage data. In the consist-
ently uncovered group, 82 % had three or more interviews
and 26 %missing data. The inconsistently covered group had
92 %with three ormore interviews and 22 %missing data.
Statistical analysis
Proportional differences between participants experiencing
sufficient or insufficient coverage at their first interview and
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their most recent interview were tested using chi-square
statistics for categorical variables and Wilcoxon rank-sum
testing for non-parametric continuous variables. Propor-
tional differences between the three coverage pattern
groups at first interview were tested using chi-square statis-
tics for categorical variables and Kruskal-Wallis testing for
non-parametric continuous variables.
Logistic regression was used to determine cross-sectional
predictors of insufficient coverage from the dichotomous
recent coverage variable. Initial inspection suggested that a
binary coverage pattern variable of consistently covered/in-
consistently covered be examined (placement in the incon-
sistently covered group as the outcome of interest), with
too few cases of those consistently uncovered to allow ana-
lysis. The chosen time point of analysis was the first inter-
view for each participant so as to minimise any bias across
time due to differences in number of interviews.
Statistical significance was set at p < 0.05. All analyses
were carried out using Stata 13.1 for Windows (Stata-
Corp LP, TX, USA).
Results
Participant demographics
At first interview, the amended sample of 502 partici-
pants was predominately male (64 %), Australian-born
(82 %), largely non-indigenous (95 %), unemployed
(78 %) and living in stable accommodation (85 %). Mean
age at first interview was 30. For those reporting inject-
ing within the month prior to interview (n = 416), heroin
was the most commonly injected drug (73 %), followed
by methamphetamine (11 %). The remaining 16 % of
participants most commonly injected either some form
of OST or other pharmaceutical opioid.
Coverage characteristics across the cohort
Participants who reported syringe acquisition in the two
weeks before interview collected syringes from any
source a median of two times (interquartile range (IQR):
1–3) at both first and most recent interview. Participants
collected a median of 20 syringes at first and most re-
cent interview (IQRs of 10–70 and 10-100 respectively),
and gave away/sold a median of one syringe (IQR: 0–8)
at first interview and zero syringes (IQR: 0–10) at most
recent interview. After subtraction of distributed syrin-
ges, participants retained a median of 16 syringes at both
their first and most recent interview (IQRs of 6–48 and
5–65 respectively).
For those not reporting injecting abstinence in the
week before interview, median self-reported injecting
frequency was five times (IQR: 2–11) at both first and
most recent interview (IQR: 2–14).
Median coverage percentages at first and most recent
interview were 165 % (IQR: 92–353 %) and 175 % (IQR:
100–357 %) respectively. Despite the median percentage
coverage being greater than 100 %, recent insufficient
coverage was substantial; 26 % and 25 % of the sample
were insufficiently covered at their first and most recent
interview respectively.
The percentages of participants with recent sufficient
coverage across all interviews are presented in Fig. 1.
Cross-sectional sufficient/insufficient coverage across
exposure sub-groups
Proportions of sufficient and insufficient coverage were
stable over time across many sub-groups. Those with in-
sufficient coverage were more likely to report episodes
of increased injecting frequency lasting ≥1 month in the
past six months (X2 = 4.28, p = 0.039) and recent injec-
tion of methamphetamine (X2 = 15.18, p = <0.001).
Those with sufficient coverage were more likely to re-
port injecting careers equal to or longer than 13 years
(X2 = 15.63, p = <0.001) and current OST prescription
(X2 = 12.11, p = 0.001). These findings were significant at
most recent interview, but not at first interview.
Fig. 1 Percentages of sufficient coverage across interview waves
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Participants arrested within the past twelve months were
more likely to report insufficient coverage at first inter-
view (X2 = 3.91, p = 0.048), but not at most recent.
Insufficient coverage was also associated with risk
practices. Those with insufficient coverage were more
likely to report receptive syringe sharing within the past
month at first interview (X2 = 7.49, p = 0.006). Further-
more, those with insufficient coverage recorded higher
injecting risk scores on the BBV-TRAQ-SV scale at both
interviews, a difference that was significant at most re-
cent interview (p = 0.022), but not first.
At first interview, participants with current HCV in-
fection were more likely to report insufficient coverage
(X2 = 8.78, p = 0.012). This finding was confirmed in re-
gression analysis, which identified greater odds of insuf-
ficient coverage for those with a current HCV infection
(adjusted odds ratio (AOR)) = 4.44 (95 % confidence in-
tervals (CIs): 1.43, 13.73)). There was little difference in
coverage between HCV status subgroups at most recent
interview. Regression analysis also showed reduced odds
of insufficient coverage for participants who reported
most commonly acquiring syringes from NSPs (as op-
posed to pharmacies or informal sources) (AOR = 0.27
(95 % CIs: 0.09, 0.77)).
Full descriptive and regression results are presented in
Table 1.
Coverage pattern group categorisation
Of participants with valid data for coverage pattern cat-
egorisation (n = 322), 162 (50 %) were consistently cov-
ered, 17 (5 %) were consistently uncovered and 143 (45 %)
were inconsistently covered.
Median coverage across interviews for the total cohort
was 150–167 %. The consistently covered group had
greater median levels at every interview wave (214–250 %);
the reverse was true for the consistently uncovered group,
who experienced at least a 50 % shortfall in median cover-
age (45–50 %). Inconsistently covered participants recorded
over 100 % median coverage (102–117 %).
Longitudinal median coverage data are presented in
Fig. 2.
Correlates of coverage pattern groups at first interview
Most exposure sub-groups were proportionally similar be-
tween coverage pattern groups. However, some significant
differences were found.
Those consistently covered were significantly less likely
to have receptively shared syringes within the past month
(X2 = 9.58, p = 0.008) than the other coverage pattern
groups. They were also significantly more likely to have
injecting careers equal to or longer than 13 years (X2 =
6.58, p = 0.037) and current OST prescription (X2 = 12.60,
p = 0.002).
In regression analysis, two significant results were found.
Those with a current prescription of OST had decreased
odds of being classified as inconsistently covered (AOR=
0.41 (95 % CIs: 0.22, 0.76)), whilst those with a current
HCV infection had increased odds of being classified as in-
consistently covered (AOR = 2.73 (95 % CIs: 1.12, 6.64)).
Full descriptive and regression results are presented in
Table 2.
Discussion
We conducted longitudinal analysis of individual syringe
coverage to address the gap noted in previous research
[11] and to better understand the characteristics and
predictors of coverage.
We found substantial levels of insufficient coverage.
Across interview waves, the percentage of participants
experiencing insufficient coverage was between 22–36 %,
a finding that accords with previous Australian research
[2, 12]. The fact that, at any time point, between a fifth to
a third of the sample have “uncovered” injecting episodes
is of serious concern, particularly considering that insuffi-
ciently covered participants in this study had a greater
tendency to report receptive sharing of syringes, another
finding that confirms past research [2, 11].
Analysis of longitudinal coverage patterns showed that
most participants were consistently able to achieve suffi-
cient coverage across interviews. The levels of insuffi-
cient coverage seen at each interview wave were driven
then, not by those consistently uncovered but by those
who fluctuated between states of coverage over time.
This oscillating group should be the focus of interven-
tions designed to reduce insufficient coverage. That so
many participants were able to cover themselves at some
time points but not at others, suggests a relationship be-
tween individual coverage and temporal context, rather
than a consistent pattern of deficient coverage.
Cross-sectional analysis revealed that NSP access was
associated with higher levels of coverage. This finding is
plausible and highlights the advantages of harm reduc-
tion services from which PWID can reliably acquire sy-
ringes for free. These services overcome the inherent
barriers of commercial sources (such as pharmacies) and
potentially inconsistent or unreliable sources (such as
friends and partners).
The association between insufficient coverage and
current HCV infection (RNA positive) was strong. Previ-
ous research has shown that knowledge of HCV negativity
can moderate injecting risk behaviours, such as receptively
sharing syringes or injecting equipment [24]. A similar as-
sociation between HCV status and coverage may be
hypothesised, whereby a current HCV infection confers a
consequent negligence with regards to sufficient syringe
acquisition. Conversely, the shortfall in coverage might be
a driver of HCV transmission.
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Table 1 Analysis of recent sufficient and insufficient coverage at first and most recent interview
First interview
<100 %, n (%)
First interview











AORa at first interview,




Female 27 (36 %) 84 (39 %) 0.673 23 (32 %) 81 (38 %) 0.393 1
Male 47 (64 %) 130 (61 %) 47 (68 %) 132 (62 %) 1.37 (0.61, 3.09) 0.442
Indigenous status
No 66 (92 %) 200 (93 %) 0.606 62 (91 %) 202 (95 %) 0.270 1
Yes 6 (8 %) 14 (7 %) 6 (9 %) 11 (5 %) 1.04 (0.26, 4.20) 0.956
WHO definition of youth
≤24 years 11 (15 %) 41 (19 %) 0.408 3 (4 %) 9 (4 %) 0.983 1
>24 years 63 (85 %) 173 (81 %) 67 (96 %) 204 (96 %) 0.77 (0.23, 2.51) 0.661
Highest level of education
<yr10 23 (31 %) 63 (29 %) 0.515 15 (22 %) 59 (28 %) 0.620 1
Year 10–11 26 (36 %) 92 (43 %) 26 (38 %) 74 (35 %) 0.56 (0.23, 1.39) 0.210
Year 12/higher
educ/trade
24 (33 %) 59 (28 %) 28 (40 %) 80 (37 %) 1.61 (0.63, 4.13) 0.324
Employment status
No 63 (85 %) 175 (82 %) 0.511 56 (80 %) 168 (79 %) 0.840 1
Yes 11 (15 %) 39 (18 %) 14 (20 %) 45 (21 %) 0.94 (0.29, 3.01) 0.919
Weekly income
<$400 52 (70 %) 144 (67 %) 0.635 35 (50 %) 113 (53 %) 0.657 1
≥$400 22 (30 %) 70 (33 %) 35 (50 %) 100 (47 %) 0.97 (0.40, 2.35) 0.943
Stable accommodation
No 16 (22 %) 31 (14 %) 0.152 17 (25 %) 34 (16 %) 0.104 1
Yes 58 (78 %) 183 (86 %) 52 (75 %) 179 (84 %) 1.03 (0.39, 2.71) 0.956
Country of birth
Other 17 (24 %) 40 (19 %) 0.366 18 (26 %) 36 (17 %) 0.081 1
Australia 55 (76 %) 174 (81 %) 50 (74 %) 177 (83 %) 0.96 (0.37, 2.46) 0.934
Injecting career
<13 years 32 (45 %) 96 (45 %) 0.951 31 (46 %) 45 (21 %) <0.001* 1
≥13 years 40 (55 %) 118 (55 %) 37 (54 %) 168 (79 %) 0.65 (0.28, 1.53) 0.325
Heroin injection (past month)
No 9 (12 %) 38 (18 %) 0.262 10 (14 %) 39 (18 %) 0.440 1
Yes 65 (88 %) 176 (82 %) 60 (86 %) 174 (82 %) 2.30 (0.70, 7.56) 0.171
Methamphetamine injection (past month)
No 40 (54 %) 141 (66 %) 0.069 20 (29 %) 118 (55 %) <0.001* 1
Yes 34 (46 %) 73 (34 %) 50 (71 %) 95 (45 %) 1.94 (0.86, 4.39) 0.112
Hazardous drinking scale score (8 point cut-off)
abstinent 24 (33 %) 71 (33 %) 0.588 28 (40 %) 85 (40 %) 0.675 1
<8 points 27 (37 %) 90 (42 %) 23 (31 %) 77 (36 %) 0.82 (0.34, 1.98) 0.656
≥8 points 22 (30 %) 52 (25 %) 20 (29 %) 51 (24 %) 1.66 (0.63, 4.36) 0.304
Current OST prescription
No 35 (47 %) 86 (40 %) 0.199 45 (64 %) 86 (40 %) 0.001* 1
Yes 29 (53 %) 127 (60 %) 25 (36 %) 127 (60 %) 1.02 (0.49, 2.11) 0.952
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Table 1 Analysis of recent sufficient and insufficient coverage at first and most recent interview (Continued)
BBV-TRAQ-SV injecting risk scale score (continuous measure)
Mean 8.91 6.04 0.083 9.64 5.58 0.022* 1.01 (0.98, 1.03) 0.652
Receptive sharing (past month)
No 58 (78 %) 193 (91 %) 0.006* 57 (81 %) 191 (90 %) 0.054 1
Yes 16 (22 %) 20 (9 %) 13 (19 %) 21 (10 %) 1.01 (0.31, 3.36) 0.982
Injecting others (past month)
No 56 (76 %) 173 (81 %) 0.343 60 (86 %) 184 (86 %) 0.888 1
Yes 18 (24 %) 41 (19 %) 10 (14 %) 29 (14 %) 1.20 (0.47, 3.05) 0.699
Injected by others (past month)
No 66 (89 %) 186 (87 %) 0.610 68 (97 %) 192 (90 %) 0.063 1
Yes 8 (11 %) 28 (13 %) 2 (3 %) 21 (10 %) 0.32 (0.69, 1.50) 0.148
Injecting more than usual (past six months)
No 45 (61 %) 133 (62 %) 0.838 38 (54 %) 144 (68 %) 0.039* 1
Yes 29 (39 %) 81 (38 %) 32 (46 %) 68 (32 %) 1.27 (0.59, 2.76) 0.541
Solitary injecting >80 % of the time
No 48 (65 %) 152 (71 %) 0.321 52 (74 %) 154 (73 %) 0.788 1
Yes 26 (35 %) 62 (29 %) 18 (26 %) 58 (27 %) 1.43 (0.64, 3.18) 0.384
Arrest (since last interview)
No 28 (38 %) 109 (51 %) 0.048* 31 (45 %) 114 (54 %) 0.202 1
Yes 46 (62 %) 104 (49 %) 38 (55 %) 98 (46 %) 1.53 (0.70, 3.34) 0.281
HCV serology status
Negative 6 (10 %) 43 (24 %) 0.012* 6 (10 %) 19 (11 %) 0.607 1
Positive 42 (70 %) 87 (49 %) 42 (68 %) 105 (61 %) 4.44 (1.43, 13.73) 0.010*
Exposed 12 (20 %) 47 (27 %) 14 (22 %) 59 (28 %) 1.66 (0.46, 6.01) 0.436
NSP as usual source of syringe acquisition (past month)
No 12 (16 %) 20 (9 %) 0.105 20 (29 %) 31 (15 %) 0.008* 1
Yes 62 (84 %) 194 (91 %) 50 (71 %) 182 (85 %) 0.27 (0.09, 0.77) 0.015*
Regression number of observations: 215; Prob(chi2): 0.12; R2: 0.14
*Indicates statistically significant result at the <0.05 alpha level (bold data)
aAdjusted Odds Ratio, adjusted for all variables in the table
Fig. 2 Median coverage percentage across interview waves by coverage pattern groups
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AORa at first interview,




Female 67 (41 %) 6 (35 %) 49 (34 %) 0.433 1
Male 95 (59 %) 11 (65 %) 94 (66 %) 1.43 (0.72, 2.83) 0.311
Indigenous status
No 152 (94 %) 14 (88 %) 136 (96 %) 0.361 1
Yes 10 (6 %) 2 (12 %) 6 (4 %) 0.33 (0.07, 1.62) 0.172
WHO definition of youth
≤24 22 (14 %) 2 (12 %) 28 (19 %) 0.321 1
>24 140 (86 %) 15 (88 %) 115 (81 %) 1.50 (0.18, 1.37) 0.177
Highest level of education
<yr10 53 (33 %) 6 (35 %) 36 (25 %) 0.613 1
yr 10–11 64 (39 %) 6 (35 %) 66 (47 %) 1.73 (0.82, 3.62) 0.148
yr 12/higher educ/trade 45 (28 %) 5 (30 %) 40 (28 %) 2.14 (0.92, 5.01) 0.078
Employment status
No 125 (77 %) 15 (88 %) 118 (83 %) 0.348 1
Yes 37 (23 %) 2 (12 %) 25 (17 %) 0.91 (0.37, 2.23) 0.838
Weekly income
<$400 109 (68 %) 10 (59 %) 101 (71 %) 0.581 1
≥$400 52 (32 %) 7 (41 %) 42 (29 %) 1.01 (0.48, 2.13) 0.976
Stable accommodation
No 21 (13 %) 2 (12 %) 22 (15 %) 0.801 1
Yes 141 (87 %) 15 (88 %) 121 (85 %) 1.03 (0.44, 2.41) 0.946
Country of birth
Other 24 (15 %) 5 (31 %) 29 (20 %) 0.169 1
Australia 138 (85 %) 11 (69 %) 113 (80 %) 0.93 (0.38, 2.25) 0.873
Injecting career
<13 years 58 (36 %) 8 (50 %) 71 (50 %) 0.037* 1
≥13 years 104 (64 %) 8 (50 %) 71 (50 %) 0.62 (0.30, 1.25) 0.181
Heroin injection (past month)
No 41 (25 %) 2 (12 %) 24 (17 %) 0.120 1
Yes 121 (75 %) 15 (88 %) 119 (83 %) 1.26 (0.47, 3.34) 0.645
Methamphetamine injection (past month)
No 108 (67 %) 11 (65 %) 92 (64 %) 0.910 1
Yes 54 (33 %) 6 (35 %) 51 (36 %) 0.93 (0.46, 1.87) 0.842
Hazardous drinking scale score (8 point cut-off)
abstinent 53 (33 %) 5 (29 %) 41 (29 %) 0.827 1
<8 points 69 (43 %) 9 (53 %) 62 (44 %) 1.17 (0.57, 2.40) 0.673
≥8 points 39 (24 %) 3 (18 %) 39 (27 %) 1.42 (0.59, 3.42) 0.437
Current OST prescription
No 54 (33 %) 11 (65 %) 72 (50 %) 0.002* 1
Yes 108 (67 %) 6 (35 %) 71 (50 %) 0.41 (0.22, 0.76) 0.005*
BBV-TRAQ-SV injecting risk scale score (continuous measure)
Mean 6.03 9.88 5.96 0.293 0.97 (0.97, 1.02) 0.776
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We identified a persistent association between cover-
age and OST prescription. Cross-sectionally, those with
a current OST prescription had significantly higher pro-
portions of sufficient coverage (an outcome Bluthenthal
et al. [11] also identified), and longitudinally, current
OST prescription was significantly associated with being
in the “consistently covered” group. We suspect that the
key driver here is the efficacy of OST in reducing opiate
use [20, 25]. Receipt of OST has been shown to reduce
the risk of HCV incidence amongst Australian heroin
injecting PWID almost five-fold [26], whilst internation-
ally, combined OST prescription with sufficient
individual-level coverage (termed “full harm reduction”)
has been associated with an almost 80 % decrease in the
risk of HCV acquisition [27]. The role of OST prescrip-
tion in reducing HCV transmission is reflective of a re-
duction in injecting risk. Subsequently, the expansion of
OST provision may play an important role in increasing
coverage levels. Victorian OST services, however, are
currently hampered by insufficient prescribers and ineffi-
ciencies in service co-ordination [28]. Increasing the
numbers of PWID in receipt of OST would require
strategies to overcome these barriers.
Though Australia’s harm reduction provision is com-
prehensive, with at least one source of syringe distribu-
tion per 30 PWID [16], the proportions of insufficient
coverage in this and similar Australian research [2, 12,
17] indicate ongoing shortfalls. One explanation is that
the PWID population is dynamic and diverse. The vari-
ance in individual coverage is undoubtedly due to more
factors than we’ve captured here (as evidenced by the re-
gression model’s low R2 value). To appropriately account
for this diversity, harm reduction services must be adap-
tive and flexible. Consequently, the acquisition of sterile
syringes should be facilitated as much as possible by
expanding hours of NSP operation and implementing
novel methods of syringe distribution (such as syringe
vending machines, which are not widely available in
Table 2 Descriptive and logistic regression analysis of coverage pattern groups at first interview (Continued)
Receptive sharing (past month)
No 150 (93 %) 12 (71 %) 124 (87 %) 0.008* 1
Yes 11 (7 %) 5 (29 %) 19 (13 %) 1.10 (0.36, 3.35) 0.865
Injecting others (past month)
No 137 (85 %) 13 (76 %) 119 (83 %) 0.686 1
Yes 25 (15 %) 4 (24 %) 24 (17 %) 0.97 (0.40, 2.32) 0.945
Injected by others (past month)
No 145 (90 %) 16 (94 %) 128 (90 %) 0.830 1
Yes 17 (10 %) 1 (6 %) 15 (10 %) 1.66 (0.44, 6.23) 0.452
Injecting more than usual (past six months)
No 107 (66 %) 12 (71 %) 88 (62 %) 0.625 1
Yes 54 (34 %) 5 (29 %) 54 (38 %) 1.55 (0.80, 3.00) 0.191
Solitary injecting >80 % of the time
No 101 (67 %) 8 (50 %) 96 (71 %) 0.240 1
Yes 50 (33 %) 8 (50 %) 40 (29 %) 0.99 (0.50, 1.96) 0.985
Arrest (since last interview)
No 89 (55 %) 6 (35 %) 64 (45 %) 0.090 1
Yes 45 (45 %) 11 (65 %) 79 (55 %) 1.28 (0.68, 2.40) 0.439
HCV serology status
Negative 27 (21 %) 2 (17 %) 16 (14 %) 0.451 1
Positive 65 (50 %) 8 (66 %) 68 (61 %) 2.73 (1.12, 6.64) 0.027*
Exposed 37 (29 %) 2 (17 %) 28 (25 %) 2.31 (0.87, 6.13) 0.093
NSP as usual source of syringe acquisition (past month)
No 14 (9 %) 4 (25 %) 18 (13 %) 0.149 1
Yes 137 (91 %) 12 (75 %) 120 (87 %) 0.96 (0.36, 2.54) 0.933
Regression number of observations: 212; Prob(chi2): 0.25; R2: 0.10
*Indicates statistically significant result at the <0.05 alpha level (bold data)
aAdjusted Odds Ratio, adjusted for all variables in the table
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Melbourne) [29–31]. NSPs are an efficacious, cost-
effective means of limiting disease spread [14, 32, 33],
and recent modelling suggests increases in service cover-
age would decrease BBV prevalence [34, 35].
Finally, research on individual coverage levels highlight
the inadequacy of population-level measurements (such as
the WHO measure). Though logistically difficult to
determine, individual-level measurements capture the
micro-details of coverage that are often diluted in
population-wide averages. For example, at first interview
in our cohort, 14,525 syringes were reportedly acquired by
338 currently injecting participants within the two weeks
before interview, or an average of 43 syringes per person.
If this average was multiplied by 26 to extrapolate to the
total weeks in the year, this equals 1118 syringes per
PWID, nearly six times the WHO recommendation for
syringe distribution to curtail HIV spread [6]. However, it
is clear that in aggregate, the PWID who cover their
injecting episodes mask those who do not, and those who
do not cover themselves are at most risk.
Limitations
To measure individual levels of coverage, separate pa-
rameters are required, all prone to reporting bias.
Such a limitation is an unavoidable element of this
field of study [11, 12]. However, PWID recall reliabil-
ity has been demonstrated [36], and we chose the
past two weeks as the recall period for the questions
to minimise recall bias.
Recent research has shown that many PWID exploit
Australia’s unlimited dispensation policy and stockpile
syringes for future use [17], meaning that participants
who reported no past two-week syringe acquisition
may still have been sufficiently covered. These find-
ings came after MIX survey development and we
were unable to account for stockpiling in our dataset.
However, McCormack et al. found that the inclusion
of a stockpiling question decreased levels of insuffi-
cient coverage (also using Bluthenthal et al.’s meas-
ure) by only eight percentage points (24 to 16 %)
across their sample [17], so we are confident in the
patterns we observed.
A substantial amount of coverage data was missing
from our dataset. Approximately 45 % of our observa-
tions lacked coverage data, mostly (72 %) due to past
week injection abstinence. However, the remaining
28 % of missing data was due to no reported syringe
acquisition within the past two weeks and, with many
of these participants also reporting injecting (some-
times in significant frequencies), syringe stockpiling
was probably occurring. Therefore, we restricted ana-
lysis to those participants reporting both injecting and
concurrent syringe acquisition.
Finally, our participants were recruited from a
population with unknown parameters, limiting the
generalisability of our findings [37].
Conclusion
We explored individual needle and syringe coverage longi-
tudinally. We replicated previous Australian research and
found substantial insufficient coverage amongst our
group. This coverage shortfall is driven mainly by partici-
pants who cover themselves intermittently, suggesting the
influence of temporal factors. Statistical analysis showed
the protective effects of current OST prescription and
NSPs as the main source of syringe acquisition, and an in-
creased risk for those currently infected with HCV. An in-
crease in OST coverage would potentially see a concurrent
increase in syringe coverage, whilst more generally, to en-
sure PWID have every opportunity to avoid BBV infec-
tions and other injecting-related problems, the best
response is the general expansion of NSP services.
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